Proteomics International Laboratories Ltd. (AU:PIQ)
ASX:PIQ
Want to see AU:PIQ full AI Analyst Report?
PIQ Stock Chart & Stats
AU$0.67
AU$0.03(4.23%)
At close: 4:00 PM EST
AU$0.67
AU$0.03(4.23%)
Day’s Range― - ―
52-Week RangeAU$0.21 - AU$0.86
Previous CloseN/A
Volume90.30K
Average Volume (3M)426.90K
Market Cap
AU$43.77M
Enterprise ValueAU$29.35M
Total Cash (Recent Filing)AU$7.67M
Total Debt (Recent Filing)AU$681.45K
Price to Earnings (P/E)―
Beta0.92
Next Earnings
Sep 01, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.04
Shares Outstanding165,184,000
10 Day Avg. Volume295,611
30 Day Avg. Volume426,904
Financial Highlights & Ratios
PEG Ratio-0.84
Price to Book (P/B)3.69
Price to Sales (P/S)50.61
P/FCF Ratio-7.33
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
AU$0.43Price Target Upside-35.82% Downside
Rating ConsensusModerate Sell
Number of Analyst Covering1
EPS Forecast (FY)-0.04
Revenue Forecast (FY)AU$4.30M
Bulls Say, Bears Say
Bulls Say
Diversified Revenue Streams (Diagnostics + Services)Operating both diagnostics (per-test revenues and channel partnerships) and contract proteomics services provides structural diversification of revenue. This reduces single-product dependency, enables cross-selling, and smooths demand cycles, supporting medium-term resilience of cash flows.
Proprietary Proteomics Diagnostic CapabilityA commercialized blood-based diagnostic for diabetic kidney disease indicates proprietary biomarker IP and clinical validation progress. Such assets create clinical differentiation, potential reimbursement pathways, and licensing/partnering leverage that can sustain commercial adoption over multiple quarters to years.
Low Financial LeverageMinimal debt provides balance-sheet flexibility, lowering fixed financing costs and default risk. This permits management to prioritize R&D, regulatory and commercialization spend without heavy interest burden, extending runway and strategic optionality in the medium term.
Bears Say
Severe Revenue DeclineA >70% year decline in revenue signals structural demand loss, execution setbacks, or lost contracts. Sustained top-line contraction undermines scale economics, weakens negotiation leverage with payers/partners, and makes sustaining fixed costs and commercial expansion materially harder over coming quarters.
Ongoing Operating Losses And Negative MarginsPersistent negative EBIT and net margins indicate the business is not yet delivering profitable unit economics. Continued losses erode equity, constrain reinvestment, and increase reliance on external funding, making it harder to achieve durable profitability without structural change.
Negative Operating And Free Cash FlowConsistent negative operating and free cash flow create cash burn that limits the company's ability to self-fund commercialization, regulatory activities, or scale labs. This raises financing risk and may force dilutive capital raises or cutbacks affecting long-term growth plans.
Proteomics International Laboratories Ltd. News
PIQ FAQ
What was Proteomics International Laboratories Ltd.’s price range in the past 12 months?
Proteomics International Laboratories Ltd. lowest share price was AU$0.20 and its highest was AU$0.86 in the past 12 months.
What is Proteomics International Laboratories Ltd.’s market cap?
Proteomics International Laboratories Ltd.’s market cap is AU$43.77M.
When is Proteomics International Laboratories Ltd.’s upcoming earnings report date?
Proteomics International Laboratories Ltd.’s upcoming earnings report date is Sep 01, 2026 which is in 125 days.
How were Proteomics International Laboratories Ltd.’s earnings last quarter?
Proteomics International Laboratories Ltd. released its earnings results on Feb 25, 2026. The company reported -AU$0.04 earnings per share for the quarter, missing the consensus estimate of N/A by -AU$0.04.
Is Proteomics International Laboratories Ltd. overvalued?
According to Wall Street analysts Proteomics International Laboratories Ltd.’s price is currently Overvalued.
Does Proteomics International Laboratories Ltd. pay dividends?
Proteomics International Laboratories Ltd. does not currently pay dividends.
What is Proteomics International Laboratories Ltd.’s EPS estimate?
Proteomics International Laboratories Ltd.’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Proteomics International Laboratories Ltd. have?
Proteomics International Laboratories Ltd. has 165,184,000 shares outstanding.
What happened to Proteomics International Laboratories Ltd.’s price movement after its last earnings report?
Proteomics International Laboratories Ltd. reported an EPS of -AU$0.04 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went down -2.817%.
Which hedge fund is a major shareholder of Proteomics International Laboratories Ltd.?
Currently, no hedge funds are holding shares in AU:PIQ
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Proteomics International Laboratories Ltd. Stock Smart Score
Underperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Sell
Average Price Target:
AU$0.43 (-35.82% Downside)
AU$0.43 (-35.82% Downside)
Blogger Sentiment
Bullish
AU:PIQ Sentiment 100%
Sector Average 72%
Sector Average 72%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-53.16%
12-Months-Change
Fundamentals
Return on Equity
-93.66%
Trailing 12-Months
Asset Growth
60.94%
Trailing 12-Months
Company Description
Proteomics International Laboratories Ltd.
Proteomics International Laboratories Limited operates as a medical technology company with a focus on the area of proteomics. It provides PromarkerD, a predictive test for diabetic kidney disease; and develops diagnostic tests for endometriosis and giardia. The company also offers analytical services, including specialist contract research. Proteomics International Laboratories Ltd has a research agreement with the Busselton Population Medical Research Institute and the Janssen Research & Development for the research of diabetic kidney disease treatment; and partnership with QIMR Berghofer Medical Research Institute for the detection of oesophageal adenocarcinoma. The company was founded in 2001 and is based in Perth, Australia.
PIQ Stock 12 Month Forecast
Average Price Target
AU$0.43
▼(-35.82% Downside)
Technical Analysis
Prescient Therapeutics Limited
―
Pharmaust Limited
―
Chimeric Therapeutics Ltd.
―
Radiopharm Theranostics Limited
―
Recce Pharmaceuticals Ltd.
―
Options Prices
Currently, No data available
---